Aerie pharmaceuticals reports second quarter 2022 financial results and provides business update

Durham, n.c.durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the second quarter ended june 30, 2022 and provides its business and pipeline objectives and financial guidance for 2022 and beyond, including its expectation to achieve cash flow break even during 2024. “aerie delivered a strong second quarter perfo
AERI Ratings Summary
AERI Quant Ranking